Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIJ821 in MDD with Suicidal Ideation
NCT04722666Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jul 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of onfasprodil in major depressive disorder (MDD), sponsored by Novartis. Started Jul 2021; status: terminated.
02
Drugs
onfasprodil
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04722666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04722666.